NCT04314401 2026-04-13National Cancer Institute "Cancer Moonshot Biobank"National Cancer Institute (NCI)Active not recruiting1,600 enrolled
NCT01116648 2026-03-05Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerNational Cancer Institute (NCI)Phase 1/2 Active not recruiting155 enrolled 34 charts
NCT04673448 2026-01-09Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerUniversity of WashingtonPhase 1 Active not recruiting18 enrolled
NCT02208375 2025-12-31mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianM.D. Anderson Cancer CenterPhase 1 Active not recruiting159 enrolled
NCT06714617 2025-11-04Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsSystImmune Inc.Phase 1 Active not recruiting120 enrolled
NCT05179824 2025-05-06Tempus Priority Study: A Pan-tumor Observational StudyTempus AIActive not recruiting1,000 enrolled